A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Phase 2
Withdrawn
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: IV infusionOther: Placebo
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 16
- Registration Number
- NCT06833931
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06667453
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada
🇬🇧University College London Hospitals NHS Foundation Trust, London, UK, United Kingdom
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
Phase 1
Recruiting
- Conditions
- Myotonic Dystrophy 1
- Interventions
- Drug: PGN-EDODM1 for infusionOther: Placebo
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 32
- Registration Number
- NCT06204809
- Locations
- 🇺🇸
UCI Center for Clinical Research, Irvine, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Rare Disease Research, Atlanta, Georgia, United States
A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- PepGen Inc
- Target Recruit Count
- 7
- Registration Number
- NCT06079736
- Locations
- 🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
🇨🇦Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada
🇨🇦Children's Hospital of Eastern Ontario (CHEO), Ottawa, Ontario, Canada